Does F-18 FDG PET/CT actually give additional information in prostate cancer patients?

Abstract

1635

Objectives: Limitations of F-18 FDG PET study have been reported in patients with prostate cancer. The purpose of this study was to evaluate the clinical utility of FDG PET/CT in initially diagnosed prostate cancer patients. Methods: FDG PET/CT studies obtained from 30 patients with cT2-3N0M0 prostate cancer (age range: 54-80 years, mean age: 71.5 years) were retrospectively reviewed. Final diagnoses were based on pathological reports obtained from biopsy of the prostate gland. Whole-body FDG PET/CT study was performed in every patient to stage and detect double cancers. The values of SUV in the foci with increased FDG were compared with the Gleason sores. Results: Of the 30 prostate cancer patients, 2 (6.6%) patients were upstaged and 2 (6.6%) patients were found to have another cancer by FDG PET/CT study with the results of as follows: one had common iliac lymph node metastasis, one multiple bone metastases, one asymptomatic colon cancer, and one asymptomatic lung cancer. The values of SUV in the primary lesions were correlated with Gleason scores, but with no or little uptake in Gleason score of <6. Conclusions: FDG PET/CT might be useful to grade in Gleason score and to detect unexpected and asymptomatic another cancer in patients with prostate cancer.